Relationship of body mass index with BRAF V600E mutation in papillary thyroid cancer
- 162 Downloads
Current evidences suggest an influence of overweight body mass index (BMI) on the carcinogenesis in malignancies. However, the role of BMI is unclear in papillary thyroid cancer (PTC). The aim of the present study is to investigate the relationship between BMI and BRAF V600E mutation status in PTC. BRAF V600E mutation in 108 patients with PTC was analyzed by Sanger sequencing. The cutoff point of BMI was identified by X-tile for predicting mutation by overweight. Odds ratios (OR) and 95 % confidence interval (CI) of BRAF V600E mutation according to BMI and clinicopathologic variables were calculated using logistic regression models. Fifty-one patients were positive for BRAF V600E mutation. A positive relationship existed between BRAF V600E mutation and BMI (p = 0.039). A 24.3 kg/m2 was identified as cutoff point for differentiating greater than 52.0 % observed probability of mutation for BRAF V600E in entire cohort, which was similar to the midpoint between the upper limit of normal BMI and overweight defined by WHO (≥24 kg/m2). Multivariate analysis confirmed the association between BRAF V600E mutation with overweight BMI range (OR 7.645, 95 % CI 1.275–45.831, p = 0.026). This study suggests an influence of overweight BMI on the status of BRAF V600E in patients with PTC, whereas the underlying mechanism need to be further investigated.
KeywordsBody mass index BRAF mutation Papillary thyroid cancer Overweight
This work was supported by funds from the National Science Foundation of China (No. 81572622 and No. 81272934 to QHJ), the Shanghai Rising-Star Program (No. 15QA1401100 to YLW), and the Project Sponsored by the Scientific Research Foundation for the Returned Overseas Chinese Scholars, State Education Ministry (to TL).
Compliance with ethical standards
Written informed consent from all the patients was provided. This study was approved by the Ethical Committee of the Shanghai Cancer Center of Fudan University.
Conflicts of interest
- 11.Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, Veronese S, et al. Oncogenic activation of the ras/raf signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res. 2007;67:2643–8.CrossRefPubMedGoogle Scholar
- 12.Sobin LHGM, Wittekind CH, UICC. TNM classification of malignant tumors. 7th ed. New York: Wiley-Liss; 2009.Google Scholar
- 15.Campbell PT, Newton CC, Newcomb PA, Phipps AI, Ahnen DJ, Baron JA, Buchanan DD, Casey G, Cleary SP, Cotterchio M, Farris AB, Figueiredo JC, Gallinger S, Green RC, Haile RW, Hopper JL, Jenkins MA, Le Marchand L, Makar KW, McLaughlin JR, Potter JD, Renehan AG, Sinicrope FA, Thibodeau SN, Ulrich CM, Win AK, Lindor NM, Limburg PJ: Association between body mass index and mortality for colorectal cancer survivors: Overall and by tumor molecular phenotype. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2015.Google Scholar
- 27.Wang Y, Ji M, Wang W, Miao Z, Hou P, Chen X, et al. Association of the T1799A BRAF mutation with tumor extrathyroidal invasion, higher peripheral platelet counts, and over-expression of platelet-derived growth factor-B in papillary thyroid cancer. Endocr Relat Cancer. 2008;15:183–90.CrossRefPubMedGoogle Scholar
- 30.Eveleth PB, Andres R, Chumlea WC, Eiben O, Ge K, Harris T, et al. Uses and interpretation of anthropometry in the elderly for the assessment of physical status. Report to the nutrition unit of the world health organization: the expert subcommittee on the use and interpretation of anthropometry in the elderly. J Nutr Health Aging. 1998;2:5–17.PubMedGoogle Scholar
- 32.Faruk Aykan N, Yildiz I, Sen F, Kilic L, Keskin S, Ciftci R, et al. Effect of increased body mass index (BMI) on time to tumour progression (TTP) in unresectable metastatic colorectal cancer (MCRC) patients treated with bevacizumab-based therapy. Med Oncol. 2013;30:679.CrossRefPubMedPubMedCentralGoogle Scholar
- 36.Rodriguez-Cuevas S, Labastida-Almendaro S, Cortes-Arroyo H, Lopez-Garza J, Barroso-Bravo S. Multifactorial analysis of survival and recurrences in differentiated thyroid cancer. Comparative evaluation of usefulness of ages, macis, and risk group scores in Mexican population. J Exp Clin Cancer Res. 2002;21:79–86.PubMedGoogle Scholar
- 37.Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab. 2003;88:5399–404.CrossRefPubMedGoogle Scholar